Anixa Biosciences, Inc. (ANIX)
NASDAQ: ANIX · Real-Time Price · USD
3.400
+0.025 (0.74%)
At close: Sep 26, 2025, 4:00 PM EDT
3.320
-0.080 (-2.35%)
After-hours: Sep 26, 2025, 4:32 PM EDT
Anixa Biosciences Employees
As of October 31, 2024, Anixa Biosciences had 5 total employees, including 4 full-time and 1 part-time employees. The number of employees did not change compared to the previous year.
Employees
5
Change (1Y)
n/a
Growth (1Y)
n/a
Revenue / Employee
n/a
Profits / Employee
-$2,223,000
Market Cap
111.92M
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Oct 31, 2024 | 5 | 0 | - |
| Oct 31, 2023 | 5 | 0 | - |
| Oct 31, 2022 | 5 | 0 | - |
| Oct 31, 2021 | 5 | 1 | 25.00% |
| Oct 31, 2020 | 4 | -4 | -50.00% |
| Oct 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Oct 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Oct 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Oct 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Oct 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| UnitedHealth Group | 400,000 |
| Johnson & Johnson | 138,100 |
| Thermo Fisher Scientific | 125,000 |
| Abbott Laboratories | 114,000 |
| AstraZeneca | 92,900 |
| Novo Nordisk | 77,349 |
| Novartis AG | 75,883 |
| Merck & Co. | 75,000 |
ANIX News
- 5 days ago - Cleveland Clinic to Present Final Results of Phase 1 Clinical Trial for Anixa Biosciences' Breast Cancer Vaccine at 2025 San Antonio Breast Cancer Symposium - PRNewsWire
- 19 days ago - Anixa Biosciences and Moffitt Cancer Center Complete Dosing of Fourth Cohort in Ovarian Cancer CAR-T Clinical Trial; Multiple Patients Surpassing Median Expected Survival - PRNewsWire
- 25 days ago - Anixa Biosciences Announces Time Change for Presentation at the H.C. Wainwright 27th Annual Global Investment Conference - PRNewsWire
- 4 weeks ago - Anixa Biosciences to Present at the H.C. Wainwright 27th Annual Global Investment Conference - PRNewsWire
- 5 weeks ago - Anixa Biosciences Receives Notice of Allowance from Chinese National Intellectual Property Administration for Patent Covering Breast Cancer Vaccine Technology - PRNewsWire
- 5 weeks ago - Anixa Biosciences Announces Treatment of Second Patient in Fourth Cohort of Ovarian Cancer CAR-T Clinical Trial - PRNewsWire
- 6 weeks ago - Anixa Biosciences Announces Issuance of Additional U.S. Patent for CAR-T Technology - PRNewsWire
- 7 weeks ago - Anixa Biosciences Announces Dr. Robert Wenham will speak about Immunotherapy in surviving Ovarian Cancer at the 13th Annual Ovarcoming Cancer Conference - PRNewsWire